TEL AVIV, Israel & ZURICH & NEW YORK / Sep 21, 2023 / Business Wire / Regulatory News: SHL Telemedicine Ltd. (NASDAQ: SHLT; SIX Swiss Exchange: SHLTN) (“SHL” or the “Company”), a leading provider and developer of advanced personal telemedicine solutions, announced today its results for half-year 2023, emphasizing stable revenues and strategic growth initiatives. In H1 2023, SHL maintained stable revenues while making significant...Read more
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia 15 subjects enrolled in the OPMD Natural History Study, with multiple subjects entering the eligibility period this year for entry into the BB-301 Phase 1b/2a Clinical Treatment Study Successful Closing of a $30.9 M Public Offering HAYWARD, Calif., Sept. 21, 2023...Read more
The Company closed a significant convertible debenture financing with Walmart during the quarter The Company expanded to 217 locations globally (152 corporately owned and operated) TORONTO / Sep 21, 2023 / Business Wire / Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health”, “JNH” or the “Company”) announced today its unaudited interim consolidated financial results for the second quarter of fiscal 2024, six...Read more
AUSTIN, Texas / Sep 20, 2023 / Business Wire / Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three and twelve months ended June 30, 2023, and recent updates. Fourth Quarter Fiscal Year 2023 and Subsequent...Read more
WALTHAM, Mass., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Great Elm Group, Inc. (“we,” “our,” “GEG,” “Great Elm,” or “the Company”), (NASDAQ: GEG), an alternative asset manager, today announced financial results for its fiscal fourth quarter and year ended June 30, 2023. Fiscal Fourth Quarter 2023 Highlights GEG collected incentive fees from Great Elm Capital Corp. (“GECC") for the first time in the Company’s history, totaling $1.0 million...Read more
SAN DIEGO, Sept. 18, 2023 /PRNewswire/ -- Kintara Therapeutics, Inc. (NASDAQ: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal year ended June 30, 2023 and provided a corporate update. RECENT CORPORATE DEVELOPMENTS Awarded a $2.0 million Small Business Innovation Research (SBIR) grant from the National...Read more
HONG KONG, Sept. 15, 2023 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ: PRE) (“Prenetics” or the “Company”), a leading genomics-driven health sciences company, today announced financial results for the second quarter ended June 30, 2023, along with recent business updates. Second Quarter 2023 Financial Highlights Revenue from continuing operations of US$5.7 million Adjusted EBITDA from continuing operations of US$(5.3)...Read more
Phase 1/2 dose escalation safety and preliminary efficacy of ANKET® NK cell engager, SAR'579/IPH6101, developed by Sanofi, showed it was well tolerated with observed clinical benefit in patients with R/R AML (ASCO 2023 annual meeting), FDA Fast Track Designation awarded Exclusive worldwide rights granted to Takeda to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies; $5m upfront payment to...Read more
REDWOOD CITY, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt treatment paradigms for devastating metabolic diseases, today announced its financial results for the fourth quarter and full fiscal year ended June 30, 2023. “We are delighted that we are poised to initiate sunRIZE – our Phase 3...Read more
Southlake, TX, Sept. 14, 2023 (GLOBE NEWSWIRE) -- Heart Test Laboratories, Inc. d/b/a HeartSciences (Nasdaq: HSCS; HSCSW) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, today provided a business update and reported financial results for the first quarter fiscal 2024 ended July 31, 2023. Key...Read more
Company recorded record quarterly revenue, an increase of 21.3% compared to the same quarter last year. Significantly higher net income before taxes when compared to Q1 of last year, a difference of approximately $6 million dollars, another positive back-to-back quarter trend. VICTORIA, British Columbia / Sep 14, 2023 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), an AI-driven...Read more
HACKENSACK, NJ / ACCESSWIRE / September 13, 2023 / Champions Oncology, Inc. (Nasdaq:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, today announced its financial results for its first quarter of fiscal 2024, ended July 31, 2023. First Quarter and Recent Highlights: First quarter revenue of $12.6 million, a decline of 9% Strong...Read more
Grew Q2 2023 Preliminary Revenue 18% and Preliminary Adjusted EBITDA 23% vs. Q2 2022 Evaluating Programs to Cull Approximately 10% of the Corporate Portfolio SCOTTSDALE, Ariz., Sept. 13, 2023 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its preliminary financial results for the second quarter ended June 30, 2023. Preliminary Financial...Read more
13% growth of SaaS revenue in the first half of fiscal 2023 compared to the first half of fiscal 2022 Atlanta, GA, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (“Streamline” or the “Company”) (Nasdaq: STRM), a leading provider of solutions that enable healthcare providers to proactively address revenue leakage and improve financial performance, today announced financial results for the second quarter of...Read more
DENVER, Sept. 12, 2023 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), an industry leader in providing comprehensive healthcare programs to frail seniors through the Program of All-inclusive Care for the Elderly (PACE), announced financial results for its fiscal fourth quarter and full year ended June 30, 2023. “We are enthusiastic to enter fiscal 2024 unencumbered to pursue our goals of...Read more
Company hosts 1H 2023 Financial Results and Business Update call today at 8 a.m. ET First research collaboration with biopharmaceutical company initiated for OligoPhore™ platform Partnering discussions for legacy assets progressing with conclusion of clinical development program and opening of IND as key milestones for Bentrio® and AM-125 Significant strengthening of shareholders’ equity...Read more
Key data readouts with Company’s lead drug candidate rademikibart expected in the fourth quarter of 2023 Topline results from Stage 2 of the China pivotal trial in atopic dermatitis Topline results from Global Phase 2 trial in asthma Cash balance of $131.6 million expected to support planned operations into at least 2026 SAN DIEGO and TAICANG, China, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited...Read more
PALO ALTO, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (OTC: SRNEQ), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, announces record revenue for the month of August 2023 and is providing certain preliminary...Read more
Second quarter 2023 revenues increased 48% compared to second quarter 2022 ORLANDO, FL / ACCESSWIRE / September 11, 2023 / Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW), a developer of transdermal pharmaceutical products, today announced financial and operational results for the second quarter ended July 31, 2023. Key Highlights: Generated quarterly revenue of $655,928, up 48% over Q2 2022 Revenue for six-months ended July 31,...Read more
The Company intends to increase its existing focus on inflammatory and autoimmune indications. The Company, since its inception, considered the inherent properties of AllocetraTM as an innovative, highly-differentiated modality for immune resolution across a wide variety of inflammatory and auto-immune indications with unmet medical needs that received strong interest from large pharma, physicians and patients. As part of the...Read more
Recorded First Quarter Revenue of $37.7 Million Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million Cell and Gene Therapy Facility Expansion Remains on Schedule for Opening by End of Calendar Q3 2023 TUSTIN, Calif., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...Read more
Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval CAMBRIDGE, Mass. & SALISBURY, England / Sep 07, 2023 / Business Wire / KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral,...Read more
LONDON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its unaudited interim financial results for the six months ended June 30, 2023 and provided an update on recent corporate highlights. “The first half of 2023 was highlighted by significant updates on each of our lead rare disease programs, as...Read more
First half 2023 total revenues with double-digit growth of 15.1% at €24.6 million Both Pharma and Diagnostics segments deliver strong performance, reaffirming full year 2023 guidance for total revenue growth between 10% to 15% Recently announced strategic collaboration with Lifera, a biopharmaceutical company wholly-owned by the Saudi Arabia Public Investment Fund (PIF), strengthens global genomic and multiomic footprint and secures...Read more
WILMINGTON, Del. / Sep 06, 2023 / Business Wire / Phreesia, Inc. (NYSE: PHR) (“Phreesia” or the "Company") announced financial results today for the fiscal second quarter ended July 31, 2023. "I am incredibly pleased and proud of our team’s accomplishments in the second quarter of fiscal year 2024. We continued to deliver excellent value for our clients and scale our business—all while helping patients take a more active role in their...Read more
Expect to resubmit NDA to FDA for TransCon™ PTH in October 2023; EC decision on MAA for TransCon PTH expected during the fourth quarter of 2023 U.S. and EU regulatory authorities endorsed ApproaCH as a pivotal Phase 3 trial of TransCon CNP in children with achondroplasia; enrollment completed, and topline results expected in second half of 2024 Raising full year 2023 U.S. SKYTROFA®* revenue expectations to €165 - €170...Read more
Delivers Record HSA Asset Growth, Margin Expansion Highlights of the second quarter include: Revenue of $243.5 million, an increase of 18% compared to $206.1 million in Q2 FY23. Net income of $10.6 million, compared to net loss of $10.7 million in Q2 FY23, with non-GAAP net income of $45.6 million, an increase of 62% compared to $28.1 million in Q2 FY23. Net income per diluted share of $0.12, compared...Read more
Net Revenues Increased 7% in 1H23 Year-over-Year, on a Constant Currency Basis, Signaling Positive Performance of Rx Products MIAMI & BARRANQUILLA, Colombia / Sep 05, 2023 / Business Wire / Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a leading integrated international healthcare and pharmaceutical services company, today announced its financial results for the three months ended June 30, 2023 (“2Q23”) and the...Read more
SHENZHEN, China, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aesthetic Medical International Holdings Group Limited (Nasdaq: AIH) (the “Company” or “AIH”), a leading provider of aesthetic medical services in China, announced its unaudited financial results for the six months ended June 30, 2023. Mr. ZHANG Chen, the Chairman of the Company, commented, “On August 16, 2023, I was honored to be elected as the Chairman of AIH. This...Read more
2023 Q3 positive adjusted EBITDA to be achieved Cash, bonds and money market funds of US$22.9 million as at August 31, 2023 MONTREAL, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company expects to report positive adjusted EBITDA1...Read more
Georges Rawadi was appointed Chief Executive Officer as from April 27, 2023 Celyad Oncology has received approximately EUR 9.8m in private placement commitments from historical shareholders Encouraging progress in multiplex shRNA platform development, which allows now targeting of up to four genes simultaneously, were presented at international meetings In vitro validation of NKG2D-based multi-specific CAR T-cell platform with a...Read more
Successfully closed upsized IPO, raising $88 million in gross proceeds to continue advancing pipeline of Selected TIL Therapy programs Cash position expected to fund operations into second quarter of 2025 Two Phase 1 clinical trials of lead program, TIDAL-01, in several solid tumor Indications ongoing SAN DIEGO, Sept. 01, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a...Read more
CORAL GABLES, Fla., Sept. 01, 2023 (GLOBE NEWSWIRE) -- MSP Recovery, Inc. d/b/a LifeWallet (NASDAQ: LIFW) ("LifeWallet," or the "Company"), a Medicare, Medicaid, commercial, and secondary payer reimbursement recovery and technology leader, announced it has filed its quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2023. Recent Highlights LifeWallet continued to execute and advance its business strategy as the Paid...Read more
CAMBRIDGE, England & WALTHAM, Mass. / Aug 31, 2023 / Business Wire / Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, today announces its interim results for the six-month period ended 30 June 2023 (the ‘period’). FINANCIAL PERFORMANCE Six months ended £m, unless stated otherwise 30 June...Read more
CHASKA, Minn., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (Nasdaq: LFCR) (“Lifecore” or the “Company”), a fully integrated contract development and manufacturing organization (“CDMO”), reported results for the fiscal 2023 fourth quarter and full year ended May 28, 2023. CEO COMMENTS James G. Hall, President and Chief Executive Officer of Lifecore, commented, "We completed a very busy fourth quarter finalizing our...Read more
Best-in-class anti-CTLA-4 candidates designed for more than 30-fold increase in therapeutic index, addressing patient populations where CTLA-4-mediated Treg depletion is essential for efficacy Strong efficacy signal observed in MSS CRC phase 2 single arm study for SAFEbody® ADG126 in combination with pembrolizumab at the 10 mg/kg every three weeks dosing regimen Advancing MSS CRC cohort with ten more patients at the active...Read more
PETACH TIKVA, Israel / Aug 31, 2023 / Business Wire / Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the six months ended June 30, 2023. Clinical Progress Pivotal Phase III Advanced Liver Cancer Study—Can-Fite’s pivotal Phase III liver cancer study,...Read more
GUANGZHOU, China, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended June 30, 2023. Recent Business Updates Therapy Selection and Minimal Residual Disease (MRD) Presented study...Read more
SAN RAMON, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NYSE: COO) today announced financial results for its fiscal third quarter ended July 31, 2023. Revenue increased 10% year-over-year to $930.2 million. CooperVision (CVI) revenue up 11% to $630.2 million, and CooperSurgical (CSI) revenue up 8% to $300.0 million. GAAP diluted earnings per share (EPS) of $1.71, down $0.27 or 14% from last year's third...Read more
Total Revenues of $590.2M, up 10% Year Over Year; Subscription Services Revenues of $470.6M, up 10% Year Over Year PLEASANTON, Calif., Aug. 30, 2023 /PRNewswire/ -- Veeva Systems Inc. (NYSE: VEEV), a leading provider of industry cloud solutions for the global life sciences industry, today announced results for its second quarter ended July 31, 2023. "We had a great quarter with progress across the board that was particularly...Read more
Product revenue for the first six months of 2023 increased to $22.7 million, compared to $3.9 million for the same period in 2022 Investors, including Teva Pharmaceuticals, subscribed to Alvotech’s subordinated convertible bonds for an aggregate amount of $140 million in July 2023 Expanded its existing commercialization partnerships with Teva Pharmaceuticals for the US and with Advanz Pharma for Europe Settlement reached with Johnson...Read more
Company expects increased 2023 Reported Sales Growth of 7.0% - 8.0%, Operational Sales Growth of 7.5% - 8.5%, and Adjusted Operational Sales Growth of 6.2% - 7.2%; Figures exclude the COVID-19 Vaccine Company expects 2023 Adjusted Reported Earnings Per Share (EPS) of $10.00 - $10.10, reflecting increased growth of 12.5% at the mid-point and Adjusted Operational EPS of $9.90 - $10.00, reflecting increased growth of 11.5% at the...Read more
First quarter reported net sales increased 3.5 percent year-over-year to $1.6 billion, and internal sales increased 2.8 percent. Drove adjusted operating margin1 expansion for business overall and across both Dental and Animal Health segments. Delivered first quarter GAAP earnings of $0.32 per diluted share and adjusted earnings of $0.40 per diluted share, a 25 percent increase over the prior year period. Returned $54.9 million to...Read more
NEW YORK, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and an operational update for the period ended June 30, 2023, and provided an overview of upcoming milestones. Mesoblast Chief Executive Silviu Itescu said: “We had anticipated that remestemcel-L would have been approved by the United States Food...Read more
TEANECK, N.J. / Aug 30, 2023 / Business Wire / Phibro Animal Health Corporation (Nasdaq: PAHC) (“Phibro” or the “Company”) today announced financial results for its fourth quarter and fiscal year ended June 30, 2023, and provided guidance for the year ending June 30, 2024. Highlights for the three months ended June 30, 2023 (compared to the three months ended June 30, 2022) Net sales of $255.0 million, a decrease of $0.2 million, or...Read more
Toronto, Ontario – The Newswire – August 30, 2023 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT) (OTC:VPTDF) today reported financial results for the second quarter ended June 30, 2023 (www.sedar.ca). Second-quarter highlights Ventripoint entered into a strategic collaboration with Ascend Cardiovascular, LLC, a leading provider of cardiovascular IT solutions and the two companies have signed a...Read more
WESTPORT, Conn., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today reported financial results for the fiscal quarter ended June 30, 2023. “In recent weeks we have continued to build on the favorable interim data and early evidence of single agent activity from the Phase 1/2 trial of our...Read more
On Track for September 9, 2023 PDUFA Target Action Date on NDA for Motixafortide in Stem Cell Mobilization (SCM) for Autologous Transplantation in Multiple Myeloma (MM) Signed Exclusive License Agreement to Motixafortide in Asia Region with Concurrent Equity Investment Announced Initiation of Investigator-Initiated Randomized Phase 2 Combination Trial with Motixafortide in First Line PDAC in Collaboration with Columbia...Read more
Corporate Impact Report concluded better patient outcomes and substantial cost savings, thus accelerating Company's sales growth REDWOOD CITY, CA / ACCESSWIRE / August 30, 2023 / Biotricity Inc. (NASDAQ:BTCY) ("Biotricity" or the "Company"), a leading medical diagnostic and consumer healthcare technology company, today reported that it achieved a record $14 million annualized revenue run rate in August, extending its growth by over...Read more
VANCOUVER, British Columbia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) continues to achieve significant growth, new partnerships and developing new markets while surpassing margin targets. Now, as the Company looks back at the first half of the year, it continues with confidence on its strategy to bring HealthTab™, its turnkey solution for point of care testing and data management, to...Read more
VANCOUVER, BC, Aug. 30, 2023 /CNW/ - PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) (AQSE: NARA), is pleased to announce that it has filed financial statements for the six month period ended June 30, 2023 (the "First Half 2023 Financial Statements"). The First Half 2023 Financial Statements, together with detailed information regarding the Company's financial results as set forth in the Company's...Read more
MELBOURNE, Australia, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in guideline driven genomics-based tests in health, wellness and serious disease is pleased to report annual results for the year ended June 30, 2023. GTG has had an exciting period of commercial growth over the last 12 months in our Business to Business (B2B) channel led by geneType and our...Read more
A diverse portfolio of 25+ innovative companies from around the world (founders come from: Ireland, Sri Lanka, Bulgaria, Australia, India, Brazil, the Middle East and North America) Sectors include: Digital Health, Artificial Intelligence (AI), Machine Learning (ML), Blockchain, Virtual & Augmented Reality (VR/AR), Gaming, Climate Tech Revenue for the six-month period ended June 30, 2023 was $5,516,217 compared to $2,231,880 for...Read more
Toronto, Ontario--(Newsfile Corp. - August 30, 2023) - Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FSE: 4960) ("Braxia Scientific", or the "Company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months ended June 30,...Read more
Q4'23 net revenue of $1.07 billion decreased (17)% as reported, or (17)% in constant currency, compared to Q4'22. Organic, constant-currency net revenue decreased (19)%, compared to Q4'22. Fiscal 2023 net revenue of $4.28 billion decreased (11)% as reported, or (9)% in constant currency, compared to fiscal 2022. Organic, constant-currency net revenue decreased (11)% compared to FY'22. Q4'23 net loss of $(86) million and fiscal 2023 net...Read more
Strong progression of PureTech’s Wholly Owned Pipeline, with three clinical-stage therapeutic candidates being evaluated across four clinical trials to address large patient needs in pulmonary, oncology and CNS indications, and a growing pipeline of four additional preclinical CNS programs Advancements across Founded Entities, including Karuna’s third positive registrational trial for KarXT and planned filing for FDA approval, Akili’s...Read more
Achieved two landmark milestones with OCS-01, Oculis’ lead product candidate as first investigational eye drop for both front and back of the eye indications: positive topline results in Phase 3 DIAMOND Stage 1 trial for diabetic macular edema (DME) announced in May, and in Phase 3 OPTIMIZE trial for inflammation and pain following cataract surgery announced in August Advancing clinical programs with OCS-01, OCS-02 and OCS-05,...Read more
NEW YORK, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the fourth quarter and full year ended June 30, 2023. The webcast will begin at 6.30pm EDT, Wednesday, August 30; 8.30am AEST, Thursday, August 31, 2023. It can be accessed via:...Read more
130% increase in total top-line non-GAAP Adjusted Revenue1 of C$4,416,103 for Q2 2023 over Q2 2022 225% increase in total revenue of C$2,699,668 for Q2 2023 over Q2 2022 VANCOUVER, B.C. and LAS VEGAS, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. ("Hydreight" or the "Company") (TSXV: NURS) (FSE: SO6) (OTCQB: HYDTF), a fast-growing telehealth platform enabling flexible home healthcare, is pleased to announce the...Read more
TORONTO, ON / ACCESSWIRE / August 29, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them, intended to safely and effectively destroy various cancers has released the Company's 2Q2023...Read more
NEW AND EXTENDED ALLIANCES UNDERLINE PIPELINE VALUE POTENTIAL NEW GUIDANCE FOR FULL-YEAR 2023 CONFIRMED HAMBURG, GERMANY / ACCESSWIRE / August 29, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced its financial results and corporate updates for the first half-year of 2023. HIGHLIGHTS Q2 CYBER-INCIDENT TEMPORARILY REDUNCING STRONG ORGANIC REVENUE GROWTH Group revenues...Read more
$48.7 million in cash and cash equivalents at June 30, 2023, providing expected runway to advance Company's development candidate ("DC") through Phase I clinical development in healthy human volunteers and Duchenne muscular dystrophy patients Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) ("Satellos" or the "Company"), a public biotech company developing new small...Read more
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial results for the quarter ended June 30, 2023, and provided a corporate update. Corporate highlights during the past quarter included: The...Read more
Highlights in H1 include 115.8% increase in subscription revenue, 63.3% increase in total revenue, and 167% increase in gross profit compared to the first half of 2022. Key Developments: The Company has announced 20 new commercial contracts from January 1, 2023 to date, compared to 28 contracts/extensions signed in all of FY-2022. Total Revenue to June 30 of $946,373 represents an increase of 63.3% compared to the same period in 2022...Read more
$5.5 million first six-month 2023 sales vs. $11.7 million for the same period in 2022; sales lagging by one quarter due to stocking campaign by one major customer in 2022 and further Marketplace reorganization Ended the quarter with $11.3 million in cash allowing funding for planned pipeline and technology developments Ongoing strategic corporate discussions progressing and continued planning for uplisting to...Read more
68% Increase in Product and Services Revenue; 74% Increase in Royalties Revenue WINNIPEG, Manitoba, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane Biotech”) today announced its second quarter 2023 financial results. Second Quarter Financial Highlights: Revenue from product and services for the three months ended June 30, 2023 was $484,433 an increase of 68% from $287,584 in...Read more
Toronto, Ontario--(Newsfile Corp. - August 29, 2023) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) ("LevelJump" or the "Company"), a Canadian leader in B2B telehealth solutions, is pleased to announce today it has reported financial results for the fiscal quarter ended June 30, 2023. All amounts are expressed in Canadian dollars. Financial and Operational Highlights Revenues from Canadian Teleradiology...Read more
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reports financial results for the quarter ended June 30, 2023 (“Second Quarter 2023”) and associated Company developments. Unless otherwise noted, all figures are in Canadian...Read more
$345 million in gross proceeds raised in upsized IPO, providing a projected operating runway into 4Q 2026 Phase 1 clinical trial initiated and first participant dosed ahead of schedule for lead product candidate, APG777, a fully optimized and half-life extended anti-IL-13 antibody for the treatment of atopic dermatitis Leadership further strengthened with appointments of industry leaders to its board of directors and executive team...Read more
Treated the first patient with advanced inoperable pancreatic cancer in a safety and feasibility trial in Canada in April 89% CR, two-year local recurrence-free survival of 77%, and no treatment-related grade 2 or higher late-onset toxicity reported from an analysis of four feasibility trials in 71 patients with unresectable skin and head and neck cancers Valuable land grant received in Jerusalem to enable a standalone...Read more
Completed the first tranche of a non-brokered private placement offering of units for gross proceeds of approximately CAD$1.3 million to extend cash runway into 2024 Strengthened the Board of Directors through the appointment of Dr. Gadi Riesenfeld, Former President of Pharmos Corporation (a publicly traded biotech company listed on NASDAQ) Positive imaging results from an internal preclinical study of its investigational drug...Read more
Kovo Pivots to Focus on Software Solutions; Accelerates Quarter-over-Quarter Growth +36% Company Updates 2023 ARR Projection +9% to USD$12M Vancouver, British Columbia--(Newsfile Corp. - August 28, 2023) - Kovo HealthTech Corporation (TSXV: KOVO) (the "Company" "Kovo") a leader in healthcare technology and Billing-as-a-Service - today reported its second quarter financial results for the three month period ending June 30,...Read more
Akebia to host conference call on August 25, 2023 at 9:00 a.m. ET Expects to resubmit NDA for vadadustat as a treatment for anemia due to CKD in adult patients on dialysis in Q3 2023 Reports Auryxia® (ferric citrate) net product revenue of $42.2 million for Q2 2023 and reaffirms 2023 net product revenue guidance of $175.0-$180.0 million CAMBRIDGE, Mass., Aug. 25, 2023 /PRNewswire/ -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA),...Read more
Revenues excluding Covid test sales increased 15% for fiscal 2023 vs fiscal 2022 Successfully completed inFoods® IBS pilot program with one of the largest Gastrointestinal physician groups in the US inFoods IBS completes pre-launch phase; Veteran VP of sales and national accounts hired; On track for national launch by calendar Q1 2024 IRVINE, Calif., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the...Read more
Vancouver, British Columbia - TheNewswire - August 25, 2023 - GeneTether Therapeutics Inc., (together with its wholly-owned subsidiary GeneTether, Inc., “GeneTether” or the “Company”) (CSE:GTTX), an early-stage genetic medicine company focused on developing its disruptive proprietary platform technology to significantly increase the efficiency of DNA insertion into the genome, announced today the filing of its interim condensed consolidated...Read more
Phase 1/2a clinical trial of tetraspecific T cell engager candidate MP0533 initiated in patients with relapsed/refractory AML and MDS/AML; dosing ongoing in the 4th dose cohort; initial data expected in Q4 2023 Positive MP0317 data of ongoing Phase 1 clinical trial presented at ASCO confirm proposed MOA and indicates favorable safety profile in patients with advanced solid tumors, supporting future combination studies with potential...Read more
Record second quarter and first half revenues of EUR 14.3 million (USD 15.5 million) and EUR 29.1 million (USD 31.5 million), respectively Total HIFU Q2 2023 year-over-year revenue growth of 63.6% Strong Q2 2023 year-over-year U.S. Focal One® HIFU procedure growth of 85% Received reimbursement approval in Switzerland for use of HIFU in the treatment of prostate cancer More than half of patients now enrolled...Read more
LONDON, Aug. 24, 2023 (GLOBE NEWSWIRE) -- LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its second quarter ended June 30, 2023. Second quarter 2023 revenues of $21.0 million Submitted First 510(k) Application to the U.S. Food and Drug Administration (FDA) for 5-minute COVID Ultra test Submitted COVID/Flu combo test for FDA Emergency Use Authorization...Read more
Received in July 2023, $10 million from partner, AbbVie, for achieving a major milestone in the second quarter, for the clinical-phase dermal filler product in accordance with the strategic collaboration agreement Entered into collaboration with Stratasys, a world-leading 3D printing company, with initial focus on the development of a bioprinting solution for the fabrication of CollPlant's regenerative breast...Read more
MONTRÉAL, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the “Corporation”), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated Financial Statements and MD&A for its third quarter ended June 30, 2023. Third Quarter 2023 Highlights (in Canadian dollars) June 30, 2023(3 months) June 30, 2022(3...Read more
DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates. Second Quarter 2023 Financial Highlights Cash position Cash, cash equivalents, other financial assets and marketable...Read more
Closed exchange offer Recorded a $43.4 million gain on extinguishment of preferred stock ATLANTA, GA, Aug. 23, 2023 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (the “Company,” “Regional Health,” “we”, “us” or “our”) (NYSE American: RHE) (NYSE American: RHE-PA), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, today announced its...Read more
CHANGZHOU, China, Aug. 23, 2023 /PRNewswire/ -- Jin Medical International Limited ("the Company" or "JinMed") (NASDAQ: ZJYL), a Cayman Islands holding company with Chinese operating entities that manufacture and develop wheelchairs and living aids products, today announced its financial results for the six months ended March 31, 2023 ("the period"). Financial and Operational Highlights for Six Months Ended March 31, 2023 Revenues were...Read more
Management to host conference call for investors in coming week, details to follow CARLSBAD, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the financial results for its second quarter fiscal 2023 ended June 30, 2023. All figures are in...Read more
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE